OGNOrganon & Co.
Price
+33%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, price roughly fair, growth fading, the market undecided.
Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Organon & Co. (OGN) reported revenue of $1.56B in Q2 2026 (quarter ended Jun 30, 2026), down 2.3% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $108M (6.9% of revenue). For the full year FY2025, revenue was $6.22B (−2.9% year on year) and net income $187M. Its largest product in Q2 2026 was Nexplanon Implanon NXT at $129M, 32% of the disclosed total, ahead of Hadlima at 14%.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 31, 2026Supplemental Financial Information.Regulation FD disclosure · press release
- Jul 17, 2026As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“Sun Pharma USA”), and Sun Pharma America, Inc., a wholly owned subsidiary of Sun …Other event · Form 8-K
- Jun 11, 2026The stockholders of Organon & Co. (the “Company”) approved an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan (the “Amended and Restated 2021 ISP”) at the Company’s 2026 Annual Meeting held on June 9, 2026 (the “Annual Meeting”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $398.0MThe company’s own SEC segment disclosure.
- Nexplanon Implanon NXT$129.0M32%
- Hadlima$55.0M14%
- Renflexis$44.0M11%
- Vtama$34.0M9%
- Dulera$30.0M8%
- Follistim AQ$17.0M4%
- Other (17)$89.0M22%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
Ranks #4 of 7 by RyuScore